S'abonner

Ulcerated hemangiomas: Clinical characteristics and response to therapy - 02/09/11

Doi : 10.1067/mjd.2001.112382 
Ho Jin Kim, MDa, Mary Colombo, RNb, Ilona J. Frieden, MDb
Philadelphia, Pennsylvania, and San Francisco, California 
From the Division of Pediatric Dermatology, Children's Hospital of Philadelphia,a and the University of California, San Francisco.b 

Abstract

Background: Hemangiomas represent the most common benign tumor of infancy, with ulceration its most frequent complication. Objective: Our purpose was to review our experience with this challenging problem by evaluating the clinical features, management, and therapeutic responses of ulcerated hemangiomas. Methods: A retrospective analysis of ulcerated hemangiomas at the University of California, San Francisco outpatient pediatric dermatology clinics and Oakland Children's Hospital from 1987 to 1997 was performed. Results: The medical records of 60 patients were examined. Forty-nine female and 11 male patients were seen with a female/male ratio of 4.5:1. The majority of ulcerated hemangiomas were of the plaque type (n = 50; 83%) and relatively large; 47 (78%) were larger than 6 cm2. The perineum was the single most frequently involved site, affected in 20 cases (33%). Topical antibiotics, barrier creams, and bio-occlusive dressings were used in most cases. Systemic antibiotics were used in 26 cases (43%) for overt or presumed infection. Systemic corticosteroids were used in 21 children (37%), 5 of whom did not show a response. Intralesional triamcinolone was used in 7 cases (12%), with 4 showing definite improvement. The flashlamp pulsed-dye laser was the modality used in 22 children (37%), 11 (50%) of whom showed definite improvement, 4 (18%) who showed no significant response, and 1 (5%) who showed definite worsening. Interferon alfa-2a was required in 5 patients (8%), all of whom showed improvement without appreciable neurologic side effects. Immediate surgical excision was required in only 2 cases (3%). Pain control with oral acetaminophen, acetaminophen with codeine, and topical 2.5% lidocaine ointment was effective in managing the pain of lip and perineal hemangiomas, with no side effects noted. Conclusion: No one uniformly effective treatment modality was found, and frequently several were used concurrently. The decision to use specific therapies was dependent on the age of the patient, as well as the location, size, and stage of growth or involution of the hemangioma. Our approach to management included 4 major areas: local wound care, management of infection, specific therapeutic modalities (systemic and intralesional corticosteroids, flashlamp pulsed-dye laser, and interferon alfa-2a), and pain management. (J Am Acad Dermatol 2001;44:962-72.)

Le texte complet de cet article est disponible en PDF.

Plan


 Support given to Dr Kim from a mentorship grant from the Women's Dermatologic Society.
 Reprint requests: Ho Jin Kim, MD, Division of Pediatric Dermatology, Children's Hospital of Philadelphia, Hospital of the University of Pennsylvania, 34th & Civic Center Boulevard, Philadelphia, PA 19104.
 J Am Acad Dermatol 2001;44:962-72


© 2001  American Academy of Dermatology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 44 - N° 6

P. 962-972 - juin 2001 Retour au numéro
Article précédent Article précédent
  • Effectors of inflammation in actinic prurigo
  • Jorge E. Arrese, Luciano Dominguez-Soto, Maria T. Hojyo-Tomoka, Elisa Vega-Memije, Roberto Cortés-Franco, Esther Guevara, Gérald E. Piérard
| Article suivant Article suivant
  • A randomized trial of the Hawaii SunSmart program's impact on outdoor recreation staff
  • Karen Glanz, Jason E. Maddock, Robert A. Lew, Lynn Murakami-Akatsuka

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.